Biopharmaceutical company Synspira Therapeutics reported on Wednesday the receipt of Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for its lead product SNSP113 for the treatment of people with cystic fibrosis (CF).
CF is a chronic, life-threatening, progressive disease with persistent lung infection, airway blockage due to mucus and biofilm build up and chronic inflammation, thereby limiting the person's ability to breathe over time.
Synspira received the US Food and Drug Administration's (FDA) Orphan Drug Designation for SNSP113 in October 2018.
SNSP113, a first-in-class inhaled glycochemistry-based therapeutic with a broad spectrum mechanism of action, designed to normalize mucin viscosity and improve mucus transport to increase airway clearance. It disrupts the cohesion of bacterial biofilms and interacts with the cell walls of invading bacteria to increase their permeability, reduce their viability and potentiate the efficacy of antibiotics.
Following the EMA's ODD, the company is planning to initiate a study with SNSP113 in cystic fibrosis patients, a trial that is supported in part by a development award from the Cystic Fibrosis Foundation Therapeutics Inc.
Upon approval in the EU to treat CF, SNSP113 will be eligible for ten years of market exclusivity, as well as an additional two years of market exclusivity following completion of a paediatric investigation plan (PIP).
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007